Unknown PHASE1 INTERVENTIONAL 2-arm NCT05420545

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Sponsor: Chongqing Precision Biotech Co., Ltd

Conditions Advanced Solid Tumor Cervix Cancer Metastatic Tumor Ovarian Cancer Renal Cell Carcinoma

Interventions CD70 CAR-T cells

Updated 5 times since 2022 Last updated: Aug 16, 2023 Started: Dec 31, 2021 Primary completion: Dec 31, 2023 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumor and Cervix Cancer, this trial is ongoing. The trial is conducted by Chongqing Precision Biotech Co., Ltd and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE1
Jul 2022 — Sep 2023 [monthly]

Recruiting PHASE1

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chongqing Precision Biotech Co., Ltd

Data source: Chongqing Precision Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China